Verve Therapeutics
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing
Post navigation
Next Post
Next
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
◄ Back
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact Us